1. 1002. A Daily Single Tablet Regimen (STR) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Virologically-Suppressed Adults Living with HIV and End Stage Renal Disease on Chronic Hemodialysis. (31st December 2020) Authors: Eron, Joseph J; Wilkin, Aimee; Ramgopal, Moti; Osiyemi, Olayemi; McKellar, Mehri; McKellar, Mehri; Slim, Jihad; Asmuth, David; DeJesus, Edwin; German, Polina; Blair, Christiana; Carter, Christoph C; Brainard, Diana M; Collins, Sean E; Martin, Hal Journal: Open forum infectious diseases Issue: Volume 7:Number 1(2020) Supplement Page Start: S529 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1012. Efficacy, safety and tolerability of switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in HIV-1 infected virologically-suppressed older adults in a real-world setting. (31st December 2020) Authors: Rolle, Charlotte-Paige M; Nguyen, Vu; Patel, Kiran; Cruz, Dan; Hinestrosa, Federico; DeJesus, Edwin Journal: Open forum infectious diseases Issue: Volume 7:Number 1(2020) Supplement Page Start: S534 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 1027. Long-Term Efficacy, Safety, and Durability of Ibalizumab-Based Regimens in Subgroup of TMB-202 Participants. (31st December 2020) Authors: Towner, William; DeJesus, Edwin; Schrader, Shannon; De Vente, Jerome; McGary, Colleen; Zogheib, Mohammed; Weinheimer, Steven; Mesquita, Pedro Journal: Open forum infectious diseases Issue: Volume 7:Number 1(2020) Supplement Page Start: S542 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 889. Early Discontinuations and Adverse Events Among Treatment-Naïve Patients Initiating Integrase Inhibitors in a Real-world Setting. (4th December 2021) Authors: Rolle, Charlotte-Paige M; Castano, Jamie; Nguyen, Vu; Patel, Kiran; Hinestrosa, Federico; DeJesus, Edwin Journal: Open forum infectious diseases Issue: Volume 8(2021)Supplement 1 Page Start: S535 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus. (27th March 2016) Authors: Thompson, Melanie; Saag, Michael; DeJesus, Edwin; Gathe, Joseph; Lalezari, Jay; Landay, Alan L.; Cade, Jerry; Enejosa, Jeffrey; Lefebvre, Eric; Feinberg, Judith Journal: AIDS Issue: Volume 30:Number 6(2016) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus. (27th March 2016) Authors: Thompson, Melanie; Saag, Michael; DeJesus, Edwin; Gathe, Joseph; Lalezari, Jay; Landay, Alan L.; Cade, Jerry; Enejosa, Jeffrey; Lefebvre, Eric; Feinberg, Judith Journal: AIDS Issue: Volume 30:Number 6(2016) Page Start: 869 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. A Phase IIa Study Evaluating Safety, Pharmacokinetics, and Antiviral Activity of GSK2838232, a Novel, Second-generation Maturation Inhibitor, in Participants With Human Immunodeficiency Virus Type 1 Infection. (26th November 2019) Authors: DeJesus, Edwin; Harward, Sara; Jewell, Roxanne C; Johnson, Mark; Dumont, Etienne; Wilches, Viviana; Halliday, Fiona; Talarico, Christine L; Jeffrey, Jerry; Gan, Jianjun; Xu, Jianfeng; Felizarta, Franco; Scribner, Anita; Ramgopal, Moti; Benson, Paul; Johns, Brian A Journal: Clinical infectious diseases Issue: Volume 71:Number 5(2020) Page Start: 1255 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Antiretroviral switch studies do matter. Issue 10 (October 2018) Authors: Daar, Eric S; Ruane, Peter; DeJesus, Edwin; Stellbrink, Hans-Jürgen; Molina, Jean-Michel Journal: Lancet Issue: Volume 5:Issue 10(2018) Page Start: e546 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1–Infected Adults. (1st May 2017) Authors: Gallant, Joel E.; Thompson, Melanie; DeJesus, Edwin; Voskuhl, Gene W.; Wei, Xuelian; Zhang, Heather; White, Kirsten; Cheng, Andrew; Quirk, Erin; Martin, Hal Journal: Journal of acquired immune deficiency syndromes Issue: Volume 75:Number 1(2017) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial. Issue 4 (April 2017) Authors: Sax, Paul E; DeJesus, Edwin; Crofoot, Gordon; Ward, Douglas; Benson, Paul; Dretler, Robin; Mills, Anthony; Brinson, Cynthia; Peloquin, Julie; Wei, Xuelian; White, Kirsten; Cheng, Andrew; Martin, Hal; Quirk, Erin Journal: Lancet Issue: Volume 4:Issue 4(2017) Page Start: e154 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗